Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Andreas Weigert

Michael John Parnham

Javier Mora

Gerd Geisslinger

Andreas Ernst

Mateusz Putyrski

Christina Dillmann

Bernhard Brune

Bernhard Brüne

Bernhard Bruene

Bernhard BRÜNE

An inhibitor of IL-38 is useful for treating and/or preventing cancer in a subject. A pharmaceutical composition can include an inhibitor of IL-38. A method for treating and/or preventing cancer is carried out by administering an inhibitor of IL-38 in a therapeutically effective amount. Another method is useful for identifying an inhibitor of IL-38.

Antibody inhibitors of IL-38 and methods of use thereof for treating or reducing the likelihood of cancer in a subject

The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.

N-terminally truncated interleukin-38

Growing community of inventors

Hofheim am Taunus, Germany

Andreas Weigert